Conrad E. Raab

1.3k citations

35 papers · 933 indexed · h-index 15

Impact in

Pharmacology top 2%
- Pharmacogenetics and Drug Metabolism
- Inflammatory mediators and NSAID effects
- Drug-Induced Hepatotoxicity and Protection
Organic Chemistry top 5%
- Catalytic C–H Functionalization Methods
- Cyclopropane Reaction Mechanisms
- Synthesis and Catalytic Reactions

Papers in ⓘ

Organic Chemistry 14
- Cyclopropane Reaction Mechanisms 8
- Asymmetric Synthesis and Catalysis 5
- Synthesis and Catalytic Reactions 4
Molecular Biology 13
- Chemical Synthesis and Analysis 5
- Receptor Mechanisms and Signaling 4

Co-authors: Dennis Dean (13 shared papers)Jingjun Yin (1 shared paper)Ian W. Davies (1 shared paper)Bangping Xiang (1 shared paper)Mark A. Huffman (1 shared paper)Michael P. Doyle (8 shared papers)Gregory Roos (9 shared papers)Nathan X. Yu (7 shared papers)
Journals: Drug Metabolism and Disposition (5 papers)Bioorganic & Medicinal Chemistry Letters (2 papers)The Journal of Organic Chemistry (2 papers)Journal of Pharmacology and Experimental Therapeutics (1 paper)Molecular Pharmaceutics (1 paper)
Partner nations: United States South Africa Australia

In The Last Decade

Conrad E. Raab

33 papers receiving 900 citations

Peers

Countries citing papers authored by Conrad E. Raab

Since Specialization

Citations

This map shows the geographic impact of Conrad E. Raab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Conrad E. Raab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Conrad E. Raab more than expected).

Fields of papers citing papers by Conrad E. Raab

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Conrad E. Raab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Conrad E. Raab. The network helps show where Conrad E. Raab may publish in the future.

Co-authors

The 25 scholars most cited alongside Conrad E. Raab, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Conrad E. Raab Line = papers co-authored together Conrad E. Raab links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A General and Efficient 2-Amination of Pyridines and Quinolines The Journal of Organic Chemistry ·Jingjun Yin, Bangping Xiang, Mark A. Huffman, Conrad E. Raab, Ian W. Davies	2007	151
2	Studies on Cytochrome P-450-Mediated Bioactivation of Diclofenac in Rats and in Human Hepatocytes: Identification of Glutathione Conjugated Metabolites Drug Metabolism and Disposition ·Wei Tang, Ralph A. Stearns, Stelvio M. Bandiera, Yong Zhang, Conrad E. Raab, Matthew P. Braun, Dennis Dean, Jianmei Pang, Kwan Leung, George A. Doss, John R. Strauss, Gloria Y. Kwei, Thomas H. Rushmore, Shuet-Hing Lee Chiu, Thomas A. Baillie	1999	139
3	Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats Toxicology and Applied Pharmacology ·William H. Schaefer, Jeffery W Lawrence, Amy F Loughlin, Dana A. Stoffregen, Lori Mixson, Dennis Dean, Conrad E. Raab, Nathan X. Yu, George R. Lankas, Clay B. Frederick	2003	105
4	MECHANISM-BASED INHIBITION OF HUMAN LIVER MICROSOMAL CYTOCHROME P450 1A2 BY ZILEUTON, A 5-LIPOXYGENASE INHIBITOR Drug Metabolism and Disposition ·Ping Lü, Michael Schrag, Donald E. Slaughter, Conrad E. Raab, Magang Shou, A. David Rodrigues	2003	86
5	Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization Journal of Medicinal Chemistry ·Randy R. Miller, Maria Madeira, Harold B. Wood, Wayne M. Geissler, Conrad E. Raab, Iain Martin	2020	78
6	Synthesis and Structures of (2,2-cis)-Dirhodium(II) Tetrakis[methyl 1-acyl-2-oxoimidazolidine-4(S)-carboxylates]. Chiral Catalysts for Highly Stereoselective Metal Carbene Transformations Inorganic Chemistry ·Michael P. Doyle, Qi‐Lin Zhou, Conrad E. Raab, Gregory Roos, Stanley H. Simonsen, Vincent Lynch	1996	53
7	Comparative Assessment of the Ligand and Metal Ion Binding Properties of Integrins α9β1 and α4β1 Biochemistry ·R. Blake Pepinsky, Richard A. Mumford, Ling Ling Chen, Diane R. Leone, Suzanne E. Amo, Gail Van Riper, Adrian Whitty, Brian Dolinski, Roy R. Lobb, Dennis Dean, Linda L. Chang, Conrad E. Raab, Qian Si, William K. Hagmann, Russell B. Lingham	2002	32
8	Quantitation of Physiological and Biochemical Barriers to siRNA Liver Delivery via Lipid Nanoparticle Platform Molecular Pharmaceutics ·Yan Xu, Mei Ou, Ed Keough, Jeff Roberts, Ken Koeplinger, Mike Lyman, Scott Fauty, Ed Carlini, Melissa Stern, Rena Zhang, Suzie Yeh, Elizabeth Mahan, Yì Wáng, Don Slaughter, Marian E. Gindy, Conrad E. Raab, Charles D. Thompson, Jerome Hochman	2014	30
9	Improved enantioselection for chiral dirhodium(II) carboxamide-catalysed carbon-hydrogen insertion reactions of tertiary alkyl diazoacetates Tetrahedron Letters ·Michael P. Doyle, Qi‐Lin Zhou, Conrad E. Raab, Gregory Roos	1995	28
10	A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies Nuclear Medicine and Biology ·Zhizhen Zeng, Julie A. O’Brien, Wei Lemaire, Stacey O’Malley, Patricia Miller, Zhijian Zhao, Michael A. Wallace, Conrad E. Raab, Craig W. Lindsley, Cyrille Sur, David L. Williams	2008	23
11	Observations of Rhodium‐Containing Reaction Intermediates using HPLC with ICP‐MS and ESI‐MS Detection Advanced Synthesis & Catalysis ·Christopher J. Welch, Qiang Tu, Tiebang Wang, Conrad E. Raab, Peng Wang, Xiujuan Jia, Xiaodong Bu, Darren Bykowski, Benjamin Hohenstaufen, Michael P. Doyle	2006	21
12	A Photoactivatable Prenylated Cysteine Designed to Study Isoprenoid Recognition Journal of the American Chemical Society ·Tamara A. Kale, Conrad E. Raab, Nathan X. Yu, Dennis Dean, Mark D. Distefano	2001	19
13	Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist European Journal of Pharmacology ·Richard W. Ransom, C. Meacham Harrell, Duane R. Reiss, Kathryn L. Murphy, Raymond S.L. Chang, J. Fred Hess, Patricia Miller, Stacey O’Malley, Pat J. Hey, Priya Kunapuli, Dai‐Shi Su, M. Kristine Markowitz, Michael A. Wallace, Conrad E. Raab, Allen N. Jones, Dennis Dean, Douglas J. Pettibone, Roger Freidinger, Mark G. Bock	2004	18
14	(4,0)-Dirhodium(II) tetrakis[methyl 1-acetyl-2-oxoimidazolidine-4(S)-carboxylate]. Implications for the mechanism of ligand exchange reactions Inorganica Chimica Acta ·Michael P. Doyle, Conrad E. Raab, Gregory Roos, Vincent M. Lynch, Stanley H. Simonsen	1997	17
15	METABOLISM AND PHARMACOKINETICS OF A DIPEPTIDYL PEPTIDASE IV INHIBITOR IN RATS, DOGS, AND MONKEYS WITH SELECTIVE CARBAMOYL GLUCURONIDATION OF THE PRIMARY AMINE IN DOGS Drug Metabolism and Disposition ·Maria Beconi, Ann Mao, David Q. Liu, Christopher J. Kochansky, Tony Pereira, Conrad E. Raab, Paul G. Pearson, Shuet‐Hing Lee Chiu	2003	17
16	Remote Electronic Control in the Regioselective Reduction of Succinimides: A Practical, Scalable Synthesis of EP4 Antagonist MF-310 The Journal of Organic Chemistry ·Carmela Molinaro, Danny Gauvreau, Gregory Hughes, Stephen Y. W. Lau, Sophie Lauzon, Rémy Angelaud, Paul O’Shea, Jacob M. Janey, Michael Palucki, Scott Hoerrner, Conrad E. Raab, Rick R. Sidler, Michel Belley, Yongxin Han	2009	14
17	Synthesis of the first sulfur-35-labeled hERG radioligand Bioorganic & Medicinal Chemistry Letters ·Conrad E. Raab, John W. Butcher, Thomas Connolly, Jerzy Karczewski, Nathan X. Yu, Steven J. Staskiewicz, Nigel J. Liverton, Dennis Dean, David G. Melillo	2006	13
18	Development of an efficient and selective radioligand for bradykinin B1 receptor occupancy studies Bioorganic & Medicinal Chemistry Letters ·Dai‐Shi Su, M. Kristine Markowitz, Kathy Murphy, Bang-Lin Wan, Matthew M. Zrada, C. Meacham Harrell, Stacy S. O’Malley, J. Fred Hess, Rick W. Ransom, Ray Chang, Michael A. Wallace, Conrad E. Raab, Dennis Dean, Douglas J. Pettibone, Roger Freidinger, Mark G. Bock	2004	13
19	Identification and Characterization of Isomeric Intermediates in a Catalyst Formation Reaction by Means of Speciation Analysis Using HPLC−ICPMS and HPLC−ESI-MS Analytical Chemistry ·Qiang Tu, Tiebang Wang, Christopher J. Welch, Peng Wang, Xiujuan Jia, Conrad E. Raab, Xiaodong Bu, Darren Bykowski, Benjamin Hohenstaufen, Michael P. Doyle	2006	12
20	LC/MS/MS plasma assay for the peptidomimetic VLA4 antagonist I and its major active metabolite II: for treatment of asthma by inhalation Journal of Pharmaceutical and Biomedical Analysis ·Alison L. Fisher, Elizabeth DePuy, Andrew Jayaraj, Conrad E. Raab, Matt Braun, Michel Ellis-Hutchings, Jin Zhang, John Rogers, Donald G. Musson	2002	9

About Conrad E. Raab

Conrad E. Raab is a scholar working on Organic Chemistry, Molecular Biology, Cellular and Molecular Neuroscience, Oncology and Inorganic Chemistry, having authored 35 papers that have together received 933 indexed citations. Recurring topics across this work include Cyclopropane Reaction Mechanisms (8 papers), Asymmetric Hydrogenation and Catalysis (7 papers), Neuropeptides and Animal Physiology (6 papers), Asymmetric Synthesis and Catalysis (5 papers), Pharmacogenetics and Drug Metabolism (5 papers), Chemical Synthesis and Analysis (5 papers), Receptor Mechanisms and Signaling (4 papers) and Synthesis and Catalytic Reactions (4 papers). The work is most often cited by research in Pharmacology (175 citations), Organic Chemistry (356 citations), Biochemistry (57 citations), Toxicology (20 citations) and Pharmacology (98 citations). Conrad E. Raab has collaborated with scholars based in United States, South Africa and Australia. Frequent co-authors include Dennis Dean, Jingjun Yin, Ian W. Davies, Bangping Xiang, Mark A. Huffman, Michael P. Doyle, Gregory Roos, Nathan X. Yu, Qi‐Lin Zhou and A. David Rodrigues. Their work appears in journals such as Drug Metabolism and Disposition, Bioorganic & Medicinal Chemistry Letters, The Journal of Organic Chemistry, Journal of Pharmacology and Experimental Therapeutics and Molecular Pharmaceutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact